These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28782122)

  • 41. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
    Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
    BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.
    Meini G; Dello Russo C; Allice T; Barresi R; D'Arrigo R; Falasca F; Lipsi MR; Paolucci S; Zanussi S; Antonetti R; Baldanti F; Basaglia G; Bruzzone B; Polilli E; Ghisetti V; Pucillo LP; Turriziani O; Pirazzoli A; Navarra P; Zazzi M
    J Clin Virol; 2016 May; 78():1-3. PubMed ID: 26946153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
    Littera R; Carcassi C; Masala A; Piano P; Serra P; Ortu F; Corso N; Casula B; La Nasa G; Contu L; Manconi PE
    AIDS; 2006 Aug; 20(12):1621-6. PubMed ID: 16868443
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
    Lallemant M; Le Coeur S; Sirirungsi W; Cressey TR; Ngo-Giang-Huong N; Traisathit P; Klinbuayaem V; Sabsanong P; Kanjanavikai P; Jourdain G; Mcintosh K; Koetsawang S;
    AIDS; 2015 Nov; 29(18):2497-507. PubMed ID: 26372485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exuberant Positive Patch Test to Abacavir in a Patient with the HLA-B*5701 Haplotype.
    Micozzi S; Rojas P; Rodriguez-Gamboa A; De Barrio M
    J Allergy Clin Immunol Pract; 2015; 3(6):965-7. PubMed ID: 26116952
    [No Abstract]   [Full Text] [Related]  

  • 53. Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
    Giaquinto C; Anabwani G; Feiterna-Sperling C; Nuttall J; Mompati K; Königs C; Mensa FJ; Sabo JP; Yong CL; MacGregor TR; Nguyen T; Quinson AM
    Pediatr Infect Dis J; 2014 Jul; 33(7):e173-9. PubMed ID: 24378938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urine nevirapine as a predictor of antiretroviral adherence.
    Kumar AK; Ramachandran G; Saradha B; Narendran G; Swaminathan S
    Indian J Med Res; 2006 Apr; 123(4):565-8. PubMed ID: 16783049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
    J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
    Wongtrakul J; Thongtan T; Roytrakul S; Kumrapich B; Janphen K; Praparattanapan J; Supparatpinyo K; Smith DR
    Dis Markers; 2014; 2014():315824. PubMed ID: 25580050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.